Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Merck and sanofi-aventis to Jointly Investigate Novel Combinations Against Cancer

By Pharmaceutical Processing | December 17, 2010

Merck Serono, a division of Merck KGaA, Darmstadt,
Germany, announced today that Merck, has signed a worldwide research and
development agreement with sanofi-aventis U.S. Inc., under which Merck Serono
and sanofi-aventis U.S. Inc. will collaboratively investigate novel
experimental combinations of agents that could block specific pathways in
cancer cells. This collaboration could deliver novel targeted oncology treatments
with high therapeutic potential.

The novel combinations involve Merck Serono’s MEK inhibitor MSC1936369B
(also known as AS703026), sanofi-aventis PI3K/mTOR inhibitor SAR245409 (also
known as XL765) and class I PI3K inhibitor SAR245408 (also known as XL147),
respectively.

Under the terms of this agreement, each party will be
initially responsible for conducting a Phase I dose escalation study of these product
candidates. Sanofi-aventis will be granted a research and development license
to MSC1936369B to assess safety and initial clinical activity in combination
with its PI3K inhibitor SAR245408. In conjunction, Merck Serono will be granted
a research and development license to SAR245409 in order to assess safety and
initial clinical activity in combination with its MEK inhibitor MSC1936369B.

“In the spirit of personalizing and stratifying cancer
care, it is a logical step to combine new exciting molecules across pipelines
and companies early on, to explore combined activity against cancer pathways,”
said Dr. Wolfgang Wein, Executive Vice President for Oncology at Merck Serono.
“We expect a strong synergy between both oncology units in driving the
projects forward.” “This collaboration reinforces our commitment to
maximize our portfolio and to provide better treatments for patients with
cancer” said Debasish Roychowdhury, M.D., Senior Vice President, Head of Global
Oncology, sanofi-aventis. “Combining these two promising molecules makes
eminent sense and we are excited to partner with Merck Serono.”   

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE